Belzutifan: Primary Tx for Bilat Juxtapapillary Retinal Hemangioblastoma in VHL Patient
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Belzutifan: Primary Tx for Bilat Juxtapapillary Retinal Hemangioblastoma in VHL Patient
-
Narrated by:
-
By:
About this listen
On this episode of the JVRD Author's Forum podcast, Dr. Nikhil Batra of the Dartmouth School of Medicine discusses "Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With von Hippel–Lindau Disease," published in the May/June 2025 issue of JVRD.
Host Dr. Timothy Murray and Dr. Batra discuss how belzutifan, a HIF-2α inhibitor, was used off-label to successfully treat bilateral optic nerve hemangioblastomas in a patient with Von Hippel-Lindau Disease, resulting in significant tumor regression and visual improvement. Hear how this targeted therapy may represent a promising new direction in managing complex retinal tumors that are difficult to treat with traditional approaches.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.